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Abstract
Background: Gene silencing associated with aberrant
methylation of promoter region CpG islands is an ac-
quired epigenetic alteration that serves as an alterna-
tive to genetic defects in the inactivation of tumor
suppressor and other genes in human cancers.
Aims: This study describes the methylation status of
TMS1/ASC and CASP8 genes in cervical cancer. We
also examined the prevalence of TMS1/ASC and
CASP8 genes methylation in cervical cancer tissue and
none – neo plastic samples in an effort to correlate
with smoking habit and clinicopathological features.
Method: Target DNA was modified by sodium bisul-
fite, converting all unmethylated, but not methylated,
cytosines to uracil, and subsequently amplified by
Methylation Specific (MS) PCR with primers specific
for methylated versus unmethylated DNA. The PCR
product was detected by gel electrophoresis and com-
bined with the clinical records of patients.
Results: The methylation pattern of the TMS1/ASC
and CASP8 genes in specimens of cervical cancer and
adjacent normal tissues were detected [5/80 (6.2%),
3/80 (3.75%)-2/80 (2.5%), 1/80 (1.2%) respectively].
No statistical differences were seen in the extent of
differentiation, invasion, pathological type and smok-
ing habit between the methylated and unmethylated
tissues (P >0.05).
Conclusion: The present study conclude that the fre-
quency of TMS1/ASC and CASP8 genes methylation
in cervical cancer are rare (<6%), and have no any crit-
ical role in development of cervical cancer.
Key words: Methylation, TMS1/ASC, CASP8, cervical
cancer
INTRODUCTION
Cervical cancer is the second most common cancer
and an important cause of death in women worldwide
[1]. Therefore, it is likely that host genetic and epige-
netic events play an important role in cervical carcino-
genesis .The term “epigenetic”is used to describe mi-
totically and meiotically heritable states of gene expres-
sion that are not due to changes in DNA sequence [2].
DNA methylation is an epigenetic mechanism used for
long-term silencing of gene expression. The methy-
lation pattern is established during development and is
normally maintained throughout the life of an individ-
ual. It has been shown that such epigenetic mecha-
nisms can be important in initiating tumorogenesis and
supporting the malignant state of cancer cells [3].
Apoptosis is mediated by a family of cystine pro-
teases called caspases. CASP8, located at chromosome
2q33-34, encodes caspase 8, an initiator caspase that
plays an important role in the Fas- ligand pathway [4].
Alterations of these genes have been described in sev-
eral neoplasias, such as mutations in colon cancer and
promoter hypermethylation in medulloblastomas and
neuroblastomas [5]. TMS1 gene located on 16p11.2-12
chromosome has function such as activates pro caspas-
1-8, modulates NF-KappaB activation pathway [6].
TMS1/ASC is a bipartite protein comprising two pro-
tein-protein interaction domains, a pyrin domain (PYD)
and a caspase recruitment domain (CARD). Proteins
containing these domains play crucial roles in regulat-
ing apoptosis and immune response pathways, and mu-
tations in a number of PYD- and CARDcontaining
proteins have been linked to auto-inflammatory dis-
eases and cancer [7]. This gene is also known as ASC
(Apoptosis Speck like protein containing a CARD) [8].
So, the down regulation of TMS1/ASC in breast can-
cer cell lines correlates with dense methylation on the
CpG islands [9]. Methylation of the promoter region
of TMS1/ASC has also been identified in small cell
lung cancer and non-small cell lung cancer [10], human
glioblastoma [11], ovarian tumors [12], colorectal can-
cer [13], neuroblastoma [14], and melanoma [15]. It
was appeared no correlation between methylation of
the TMS1/ASC gene and acute lymphoblastic leu-
kemia [16]. Tischoff et al. [17] reported that promoter
methylation of the proapoptotic genes CASP8 and
TMS1 are involved in the malignant epithelial liver tu-
mor. The role of epigenetic (gene inactivation) in tu-
morigenesis in gynecologic malignancies have been
poorly understood. So, we investigated the promoter
methylation status in CASP8 and TMS1 genes and re-
lationships between clinopathologic parameters and
methylation status with risk of cervical cancer.
MATERIALS AND METHODS
STUDY SUBJECTS
The case -control study involved collection of tissue
samples of 160 North Indian subjects. 80 cases were
newly diagnosed, previously untreated and histologi-
cally confirmed as cervix cancer patients. The samples
were collected from the Post graduate Institute of
Medical Education and Research (PGIMER) Chandi-
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Chandigarh. The control tissue samples (n = 80) were
collected from the same institute with no history of
cancer or pre cancer. Informed consent was obtained
from all the cases and controls.
DNA EXTRACTION
Genomic DNA was isolated from tissue samples by
the procedure of Roe et al. [18]. For the DNA methy-
lation studies, 1 ﾵg of genomic DNA was processed
and modified with sodium bisulfite using the Intergen
CpGenome DNA modification kit (Intergen, Nor-
cross, GA). Briefly, genomic DNA was modified by
sodium bisulfite, desulfonated with sodium hydroxide,
and then purified and resuspended in TE (10 mM Tris,
0.1 mM EDTA, pH 7.5). Negative control (no sample)
and positive control (in vitro methylated and bisulfite
treated human placenta DNA) were included in all re-
action . The methylation-specific (MS) PCR conditions
and the sequences of premiers are used for TMS1/
ASC and Caspes-8 previously described by Liu et al.
[19] and L￡zcoz et al . [20] respectively .
The positions of the 191bp PCR product repre-
senting the methylated and unmethylated 196 bp alle-
les for TMS1/ASC were separated on 3% agarose gels
(Fig.1). In case of Caspes-8, the PCR products for the
methylated and unmethylated alleles which separated
on 3% were 321 and 320 bp respectively (Fig.2).
STATISTICAL ANALYSIS
The results combined with the clinical records of Pa-
tients were analyzed with the the Epi-Info software
(Epi-Info, version 3.2, Centers for Disease Control
and prevention, Atlanta, GA, USA) and the software
package SPSS, version 10.0 (SPSS, Chicago, IL, USA).
Significance was set at P ≤0.05.
RESULTS
The methylation status of the TMS1/ASCand Caspase-
8 in primary cervical cancer and control non-neoplas-
tic cervix tissue specimens derived from north India
population was analyzed.
There were no methylation frequency association
for TMS1/ASC gene with various clincopathological
parameters including: age, smoking, histological type,
and stage (P >0.05) (Table 1). Similarly, same result
was observed for Caspase-8 gene with various clinico-
pathological parameters (Table.2).
The status of promoter methylation for TMS1/
ASCand Caspase-8 genes in 80 primary cervical cancer
tissue and 80 control non-neoplastic cervix tissue
specimens were examined. The promoter methylation
frequency for TMS1/ASC gene in cervical cancer
and control were 6.2% (5/80), 3.75% (3/80) respecti-
vely.
The methylation status of the Caspase-8 gene was
detected in cervical cancer tissue 2.5% (2/80 ) and
normal tissue 1/80 (1.2%). There was no deference
significant methylation frequency for the TMS1/ASC
and Caspase-8 genes as compared to controls non-neo-
plastic cervix.
DISCUSSION
The effect of DNA hypermethylation in gene promot-
er regions is similar to genetic loss-offunction muta-
tions [21]. Many cellular pathways are inactivated by
this epigenetic event, including DNA repair, cell cycle,
apoptosis, cell adherence, and detoxification [22]. The
specific patterns of CpG island hypermethylation be-
tween tumor types may provide a useful signature for
tumor diagnosis and prognosis [23]. TMS1/ASC gene
was originally identified as a target of methylation-in-
duced silencing using cell lines that over express DNA
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Fig. 1. Methylation analysis of TMS1/ASC in cer-
vical cancer. Lane U: amplified product with
primers recognizing unmethylated sequence; Lane
M: amplified product with primers recognizing
methylated sequence. NC, normal control; PC,
positive control for methylation. L: ladder (100bp).
Fig. 2. Methylation analysis CASP8 in cervical cancer. Lane U: ampli-
fied product with primers recognizing unmethylated sequence; Lane M:
amplified product with primers recognizing methylated sequence. NC,
normal control; PC, positive control for methylation. L: ladder (100bp).
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pathway mediating cell death via death receptors,
CASP8 acts as a key apoptotic enzyme by serving as
an “initiator CASP”; moreover, CASP8 was recently
shown to be silenced by aberrant methylation [24].
However, because the 5' region of CASP8 does not
contain a typical CpG island, the relevance of methy-
lation to its silencing remains unclear [25].
TMS1/ASC is a novel proapoptotic gene previously
identified as a target of DNA methylation in breast
cancer [26]. Terasawa et al. [27] showed that aberrant
methylation of the 5' region of TMS1/ASC is well
correlated with loss of expression in ovarian cancer.
Notably, decreasing TMS1/ASC expression reduces
sensitivity to chemotherapeutic drugs [28]. The methy-
lationmediated silencing of TMS1/ASC would be ex-
pected to contribute to a survival advantage for tumor
cells, by enabling them to escape apoptosis, which sup-
ports a role for aberrant methylation in human ovarian
tumorigenesis [29]. Approximately 40% (10/17) of
primary breast tumors also exhibited aberrant methy-
lation of the TMS1/ASC gene. Different studies have
confirmed the frequency of aberrant methylation of
TMS1/ASC in primary breast cancers, ranging from
10% to 40%. Methylation-associated silencing of the
TMS1/ASC gene was observed in 11% of gastric car-
cinomas, 40%-41% of small cell and non small cell
lung carcinomas, 50% of malignant melanomas, and
44% of primary glioblastomas [30, 31]. Jens et al. [32]
reported frequency of methylation for Caspase-8
(1.2%) and TMS1 (5.1%) in ovarian cancer, and con-
cluded that, methylation of these genes in regulation
of apoptosis was no significant (P = 0.74). In line of
our study Feng et al. [33] demonstrated the rate of hy-
permethylation for TMS1 to be 3.1% in controls and
6.7% in patient with cervical cancer. Liu et al. [34]
found that aberrant methylation of the TMS1 gene
was detected in tumor tissues %36.1 with Choangio
carcinoma, and in normal tissue 8.3%. So, there were
no statistical differences in age, gender, pathologic
type between the methylated and unmethylated tissues.
Aberrant methylation of TMS1 gene was detected in
15 of 80 ovarian cancer tissue (19%) but in none of
the normal ovary specimens [35]. Michalowski et al.
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Table1. The relationship between TMS1 promoter methylation and clinicopathology parameter of cervical cancer.
Characteristic overall present Absent P P Value
<50 44 2(4.5%) 42(95.4%)
0.65
>50 36 3(8.3%) 33(91.6%)
Smoker 5 1(20%) 4(80%)
0.28
Nonsmoker 75 4(5.3%) 71(94.6%)
Histological type
SCC 68 4(5.8%) 64(94.1%)
0.56
AC 12 1(8.3%) 11(91.6%)
Stage
Ib 46 1(2.2%) 45(97.8%)
IIa 12 2(16.6%)IIb 10(83.3%) 0.10
IIb 19 2(10.5%) 17(89.4%)
IIIb 3- 3(100%)
Table 2. The relationship between Caspase-8 promoter methylation and clinicopathology parameter of cervical cancer.
Characteristic overall present Absent P P Value
<50 44 0 44(100%) -
>50 36 2(5.6%) 34(94.4%)
Smoker 5 1(20%) 4(80%) 0.12
Nonsmoker 75 1(1.3%) 74(98.6%)
Histological type
SCC 68 2(2.9%) 66(97.05%)
AC 12 -
Stage
Ib 46 1(2.17%) 45(97.8%) 0.37
IIa 12 1(8.3%) 11(91.6%)
IIb 19 --
IIIb 3- -
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in neuroblastoma. Matinez et al. [37] strongly suggest-
ed that hypermethylation of the pro-apoptotic Caspase-
8 in glioblastoma (P = 0.0035). The present study’s re-
sults were consonance with those of Yang et al. [38]
who  carried  out  a  similar  study  in  Chinas  women.
However, our study has several potential limitations.
First, we were not able to in    corporate into the model
information concerning the relative level of hyperme-
thylation of each specific gene. It is possible that other
gene combinations, which may have increased sensitiv-
ity and specificity, will be identified through the use of
real-time  PCRbased  assays  such  as  MethyLight  [39],
which  provided  information  on  the  relative  level  of
hypermethylation  of  each  specific  gene  examined.
Second, we limited our search for useful hypermethy-
lated genes to an assessment of 2 genes that had been
previously reported to be associated with cancers at
other sites. Identification of additional novel CpG is-
lands that are specifically associated with cervical can-
cer will be needed to construct a panel with higher
sensitivity that maintains high specificity, and studies
examining detection of such a panel of genes using
recently developed quantitative assays should be un-
dertaken. More study using a much larger samples size
are  needed  to  further  define  the  potential  role  of
methylated DNA marker in cervical cancer manage-
ment.
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